01-08-320 13:1	7 FROM- Midd	letown Medica	al 8453	422456		T-932 F	0002/0003 F-923		
REGIONAL		**** « (=== == == ==		İ		1			
MIDICAL ARTON	•	CHEMOT	HERAPY			;			
TO BE COMPLETED	BY PHYSICIAN	ORD				Person	: Lugional		
Date Mutten:	0/2000	-		Keyes	(<u>6)</u>		1008-18/22/ED		
Diagnosis			- Date of Ada	inearation:		<u> </u>	- See 17 (
Protocol/Regimen:			TNM Stage:		,	<u></u>			
Protocol/Regiment	حرطونهج	× 14,	Cycle: of	: 14		Morgies:	□ NKDA		
	•	ade 152	Day:		B	يراجات ۾			
Venous Access.	Peripheral C	Central				acti atex	m		
Height W	eight IT Acre				l	atex	, [
= 62in 17	129 (1256) 13 13 13		ody Surface 'ea (m²)	Emetic La	Vel I	-			
	Ker Dadju	1.5T&cd	. 83 ·	_ ☐ Mode	reate (-		
rap Ordete: 10 Ci			<u></u>			i_	_		
Hold Parameters:				JUA EVE		Alc.			
ANC less than: 100	ONEC less than	PLY less t	29n: 75, Kg	After lamous states	_ ر				
N Fluider F 3 c. "	rde-st			<u>~.v⊶ ies</u> smat		Cr groater	com: L		
N Pluidz: () Sodium	Onlorida 0.8% to K	<u> </u>	Dexross 5% (KVO (20 m) /h/	_ 	or Abrusale \	Nurse initials		
			- -	- (as morn	<u></u>	<u> </u>			
Dexamete	ARRONA I	Ohio IV			 _ _				
-Cobraa 1	er e iv			<u>-</u> -	——	<u> </u>			
<u></u>					 -	<u> </u>	<u> </u>		
*Ensure en	booke	la cold or	2		_				
administr	other of	TAILY IN	20000044	45 OZ.	_ _				
		<u> </u>	<u> </u>	()	_ _		<u> </u>		
Solution. Volume and influsion rate are per manufacturer through the solution.									
Solution. Volume and infusion rate are per manufacture/hospital guidelines unless otherwise specified. Chemotherspeutic significant vial size if within 5% of calculated dose. Biological agents will be founded down to the nearest vial size if within 10% of calculated dose. Please administer chemotherspy in sequence listed below. Dose per Dose									
		Calculated dose	Please adminis	<u>Têr chamothen</u>	DA W sec	i <u>nauce</u> li≥te	nded down to		
Chemotherapy	Uak-	Reduction-	Calculated	Dispensed	[
	(m², ka, AUC)	(mg/m²,	Dose	(Rounding to be completed	Rouse	infusion Rais	RPA/ Norse		
	 -	mg/kg, AUC)		ου compie(υ σ Δν RPh)		-	initials		
Kadsella	3.6malr	and 1	201	-					
<i>\</i>	1	. "	COC-11-NATCH		<u> </u>				
						!	. 7		
	<u>_</u> _								
,			-						
'iī vaing e dosa reduct	107 plants and				{	;			
MD Name (Pring:	2 ela Mauro	Chweleid 7'''	- V						
FN Name (Print)		_	- /^	<u> </u>	Pets/Trip		H2929		
RPh Name (Print)		RN Signatun RPh Signatur		—- <u></u> _	Date/(i)	ne	<u> </u>		
		— 'vvc u -zi@nasov	·	_	Date/Tro				
·									
_	otherapy Ordero-Zunith						ФЛ гт (су до 2004-1114		
	otnarapy Ord∋rc-Zn r≻				•		⊅1maoy ος 25φ-1124		
	etnarapy Ord∋rc-Zл≀р						ФП ге бу <u>ск</u> 234-1124		
	≏tnarapy Ord∋ rc Z -r /÷		<u>.</u> .				<u></u>		
	eπαгару Оrd∋ræ⊠л /Þ		<u>-</u> 1				ФП ге бу <u>ск</u> 234-712-		
17 11	≏tnarapy Ord∋ rc. Z -л / г		<u>-</u> 1				<u>————————————————————————————————————</u>		
ar—	etnarapy Ord∋rc-Z-n /e						<u></u>		
	etnarapy Ord∋ro Zarre			4			Φήταφ α <u>ς 234</u> -1124		

01-08-120 13:18 FROM- Middle	stown Medical	8453422456	T -93 2	P0003/0003 F-923
	'A MARINE			
ORANGE REGIONAL	,		•	PAŤ)ENT LABEL
MEDICAL CENTER				
	. A. I	erapy informed c	onsent	•
I hereby euthorize Dr. " Moi administer to me the following o	dreed have been as a con-	and or as	sociates or assistants of his	her choice, to
TANITURE OF THE TOTAL PARTY OF		ng of the following drugs.		
	1. 1.	Lace Ala	· · · · · · · · · · · · · · · · · · ·	
	3, 📜			, ,
, Europe Competency of	4 5	<u> </u>		
- Charles and the	6.			
I have been fully informed of a drawback including the impact subcesse, discomforts and possibly treampent have been reviewed champitheropy infusion. I have been satisficationly. Leunderstand that during the conchemotherapy is be altered. All	on daily ectivities feld le risks that may alfa with me. Lecknowled seen given the opport uree of this chemoth	med to recuperation have be have been addressed. The gethat no guierantees or unity to ask questions, end erapy, unforessen conditions.	een discussed. The compile of elistratives, including por easurances have been give all of my questions have to the may arise which could to	ations, likelinood of ssjole results of non an to me about the seen answered fully
i understand that the medication educated me about the following	s prescribed by my of side effects that I mig	nt experience because of n	iý chemotherapy.	. My physician has
ELAnemia / Low Red Blood Ca) hu	Heir Loss/thinning Fatigue Fatigue Mouth Sores Dighthea/Constipa Electing/low plate	(jon	
. 🖳 Numbness/lingling		⊠LO(her	·	,
. I also understand that I may stop	treatment at apy time			
Y Patient/Relative Signature: ✓	Secres J. J.	eyeld Date:	6 2030 ··	<u> 5</u> 5 (2.368)
Relationship, if not patient		Date;	;1 1	
Physician Signature		Dave: ""	10/2020	Till ey Karasan
Winess to Ration Signature	V 7/	X	7-3-4	 .
Analesa to Gardin Sidilarina 1		Dete	CACCE CONTRACT	<u>. </u>
	V		;	
	. "		And the second second	
-	· . · .			
	ý			
			V.	
	. [Farm/TCÇ	C/Chemokharapy Informed C	Onsent/EE/sm/6/10
	•	′ ;	-	